Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.
Torben Plesner(University of Southern Denmark), Paul G. Richardson(Harvard University), Linda Basse(Genmab (Denmark)), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), Steen Lisby(Genmab (Denmark)), Charlotte Lemech(Unknown), Monique C. Minnema(University Medical Center Utrecht), Mary Guckert(GlaxoSmithKline (United States)), Antonio Palumbo(University Hospital Brno), Ulrik Lassen(Rigshospitalet), Tahamtan Ahmadi(Genmab (United States)), Nikolai C. Brun(Genmab (Denmark)), Henk M. Lokhorst(Amsterdam UMC Location Vrije Universiteit Amsterdam), Peter Gimsing(University of Copenhagen), Howard Yeh(Hospital de Santa Maria), Jakub Krejcik(University of Southern Denmark)
Cited by 36
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k